SCHEMBL2237065

SCHEMBL2237065

COC1NN(c2ccccc2F)C(=O)O1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 1/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
MGLL Q99685 1/20 0.38
HSD11B1 P28845 1/20 0.36
TSHR P16473 1/20 0.35
ALDH1A1 P00352 3/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
ADORA3 P0DMS8 1/20 0.34
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
HCAR1 Q9BXC0 1/20 0.33
SCN9A Q15858 1/20 0.33
LMNA P02545 1/20 0.33
HTT P42858 1/20 0.33
HIF1A Q16665 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
EPHX2 P34913 1/20 0.33
POLB P06746 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11623489 0.82 MGLL (0.38) MGLL
SCHEMBL2236268 0.82 MGLL (0.45) MEN1KMT2AMGLLALDH1A1ADORA3
SCHEMBL11620783 0.78 MAOA (0.41) GRM2MAPT
SCHEMBL11620916 0.77 RAD51 (0.36) MEN1KMT2AHCAR1NPSR1
SCHEMBL2233413 0.69 NPBWR1 (0.36) GRM2MEN1KMT2AMGLLALDH1A1
SCHEMBL11556229 0.68 ELANE (0.38) MEN1KMT2AMGLLALDH1A1SMN1; SMN2
SCHEMBL11557383 0.67 ALDH1A1 (0.41) MEN1KMT2AMGLLALDH1A1ADORA3
SCHEMBL11623153 0.67 GSK3A (0.35) MGLLHCAR1
SCHEMBL11621694 0.67 GSK3A (0.35) MEN1KMT2AMGLLALDH1A1SMN1; SMN2
SCHEMBL11618972 0.67 TSHR (0.36) MGLLHSD11B1TSHRALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8299264-B2 Method for producing oxadiazolinone compound and intermediate thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-10-30 US disclosed
US-20110207936-A1 METHOD FOR PRODUCING OXADIAZOLINONE COMPOUND AND INTERMEDIATE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-25 US disclosed
EP-2357167-A1 METHOD FOR PRODUCING OXADIAZOLINONE COMPOUND AND INTERMEDIATE THEREOF Sumitomo Chemical Company, Limited (JP) 2011-08-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207936-A1 METHOD FOR PRODUCING OXADIAZOLINONE COMPOUND AND INTERMEDIATE THEREOF AHR, CYP1B1, AR GRM2 3603/4885MEN1 2516/4885KMT2A 1740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.